Bo Ma

Dr. Bo Ma


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YLYing Lu
Ying Lu
YSYang Sun
Yang Sun
JZJianwei Zhu
Jianwei Zhu
LYLisha Yu
Lisha Yu
XJXiubo Jiang
Xiubo Jiang
Qi ZhangQi Zhang
Qi Zhang
Osteosarcoma is the most common high-grade human primary malignant bone sarcoma with lower survival in the past decades. Oridonin, a bioactive diterpenoid isolated from Rabdosia rubescens, has been proved to possess potent anti-cancer effects. However, its potential mechanism still remains not fully clear nowadays. In this study, we investigated the anticancer effect of oridonin on human osteosarcoma and illuminated the underlying mechanisms. In vitro, oridonin inhibited the cell viability of various osteosarcoma cells. We demonstrated that oridonin induced mitochondrial-mediated apoptosis by increasing Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (MMP), triggering reactive oxygen species (ROS) generation and activating caspase-3 and caspase-9 cleavage in MG-63 and HOS cells. Moreover, we found that oridonin triggered ROS by inhibiting NF-E2-related factor 2 (Nrf2) pathway and induced mitochondrial apoptosis via inhibiting nuclear factor-κB (NF-κB) activation by activating Peroxisome Proliferator-Activated Receptor γ (PPAR-γ) in MG-63 and HOS cells. We further confirmed the results by PPAR-γ inhibitor GW9662, PPAR-γ siRNA as well as overexpression of PPAR-γ and Nrf2 in vitro. Furthermore, our in vivo study showed that oridonin inhibited tumor growth with high safety via inducing apoptosis through activating PPAR-γ and inhibiting Nrf2 activation in xenograft model inoculated HOS tumor. Taken together, oridonin exerted a dramatic pro-apoptotic effect by activating PPAR-γ and inhibiting Nrf2 pathway in vitro and in vivo. Therefore, oridonin may be a promising and effective agent for human osteosarcoma in the future clinical applications.

14 September 2017 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
YWYu Wang
Yu Wang
SGSu-Han Guo
Su-Han Guo
XSXue-Jun Shang
Xue-Jun Shang
LYLi-Sha Yu
Li-Sha Yu
JZJian-Wei Zhu
Jian-Wei Zhu
Bo MaBo Ma
Bo Ma
Triptolide (TP), an oxygenated diterpene, has a variety of beneficial pharmacodynamic activities but its clinical applications are restricted due to severe testicular injury. This study aimed to delineate the molecular mechanisms of TP-induced testicular injury in vitro and in vivo. TP (5–50000 nmol/L) dose-dependently decreased the viability of TM4 Sertoli cells with an IC50 value of 669.5–269.45 nmol/L at 24 h. TP (125, 250, and 500 nmol/L) dose-dependently increased the accumulation of ROS, the phosphorylation of JNK, mitochondrial dysfunction and activation of the intrinsic apoptosis pathway in TM4 cells. These processes were attenuated by co-treatment with the antioxidant N-acetyl cysteine (NAC, 1 mmol/L). Furthermore, TP treatment inhibited the translocation of Nrf2 from cytoplasm into the nucleus as well as the expression of downstream genes NAD(P)H quinone oxidoreductase1 (NQO1), catalase (CAT) and hemeoxygenase 1 (HO-1), thus abrogating Nrf2-mediated defense mechanisms against oxidative stress. Moreover, siRNA knockdown of Nrf2 significantly potentiated TP-induced apoptosis of TM4 cells. The above results from in vitro experiments were further validated in male mice after oral administration of TP (30, 60, and 120 mg·kg−1·d−1, for 14 d), as evidenced by the detected indexes, including dose-dependently decreased SDH activity, increased MDA concentration, altered testicle histomorphology, elevated caspase-3 activation, apoptosis induction, increased phosphorylation of JNK, and decreased gene expression of NQO1, CAT and HO-1 as well as nuclear protein expression of Nrf2 in testicular tissue. Our results demonstrate that TP activates apoptosis of Sertoli cells and injury of the testis via the ROS/JNK-mediated mitochondrial-dependent apoptosis pathway and down-regulates Nrf2 activation.

3 September 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Bo MaBo Ma
Bo Ma
HZHang Zhang
Hang Zhang
YWYu Wang
Yu Wang
AZAng Zhao
Ang Zhao
ZZZhiming Zhu
Zhiming Zhu
Qi ZhangQi Zhang
Qi Zhang
The development of potent non-toxic chemotherapeutic drugs against castration resistant prostate cancer (CRPC) remains a major challenge. Corosolic acid (CA), a natural triterpenoid, has anti-cancer activity with limited side effects. However, CA anti-prostate cancer activities and mechanisms, particularly in CRPC, are not clearly understood. In this study, we investigated CA anti-tumor ability against human CRPC and its mechanism of action. The cell apoptosis and proliferation effects were evaluated via MTT detection, colony formation assay and flow cytometry. Western blot, gene transfection and immunofluorescence assay were applied to investigate related protein expression of Endoplasmic reticulum stress. A xenograft tumor model was established to investigate the inhibitory effect of CA on castration resistant prostate cancer in vivo. The results showed that CA inhibited cell growth and induced apoptosis in human prostate cancer cell (PCa) line PC-3 and DU145, as well as retarded tumor growth in a xenograft model, exerting a limited toxicity to normal cells and tissues. Importantly, CA activated endoplasmic reticulum (ER) stress-associated two pro-apoptotic signaling pathways, as evidenced by increased protein levels of typical ER stress markers including IRE-1/ASK1/JNK and PERK/eIF2α/ATF4/CHOP. IRE-1, PERK or CHOP knockdown partially attenuated CA cytotoxicity against PCa cells. Meanwhile, CHOP induced expression increased Tribbles 3 (TRIB3) level, which lead to AKT inactivation and PCa cell death. CHOP silencing resulted in PCa cells sensitive to CA-induced apoptosis. Our data demonstrated, for the first time, that CA might represent a novel drug candidate for the development of an anti-CRPC therapy.

1 May 2019 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
JZJie Zhang
Jie Zhang
XBXiaowen Bao
Xiaowen Bao
MZMingya Zhang
Mingya Zhang
ZZZhiming Zhu
Zhiming Zhu
LZLvqi Zhou
Lvqi Zhou
Bo MaBo Ma
Bo Ma

1 April 2020 in Phytomedicine
Verified
Journal Article
Closed access
AZAng Zhao
Ang Zhao
ZZZhanjie Zhang
Zhanjie Zhang
YZYanfen Zhou
Yanfen Zhou
XLXin Li
Xin Li
XLXiaotian Li
Xiaotian Li
Qi ZhangQi Zhang
Qi Zhang

10 August 2022 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
XBXiaowen Bao
Xiaowen Bao
JLJiaqi Li
Jiaqi Li
CRChaoxing Ren
Chaoxing Ren
JWJingxun Wei
Jingxun Wei
XLXuanzhao Lu
Xuanzhao Lu
Bo MaBo Ma
Bo Ma